Contact Us

SSRI Antidepressants Birth Defects
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date of birth of child : 

Date you started taking this drug:

Date you stopped taking this drug:

Was your child born with a birth defect?

Please describe birth defect side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Anti-Depressant Warning Issued

Aug 9, 2004 | The Toronto Star

Women who take some anti-depressant drugs during late pregnancy may be putting their babies at risk, Health Canada is warning.

The department issued an advisory today about the following SSRI anti-depressants: bupropion (used for depression or for smoking cessation), citalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline and venlafaxine.

International and Canadian reports reveal that some newborns whose mothers took medications containing Selective Serotonin Re-uptake Inhibitors or other newer anti-depressants during late pregnancy developed complications at birth requiring prolonged hospitalization, breathing support and tube feeding.

Reported symptoms include feeding and/or breathing difficulties, seizures, muscle rigidity, jitters and constant crying. In most cases, the anti-depressant was taken during the last three months of pregnancy.

The symptoms could indicate a direct adverse effect on the baby, or possibly a discontinuation syndrome caused by sudden withdrawal from the drug.

Health Canada said it issued the advisory to increase awareness so symptoms can be recognized and addressed quickly.

The agency is working with drug manufacturers to update labelling with new warnings.

Related articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo